Solution to 50-year-old mystery could lead to gene therapy for common blood disorders

April 2, 2018, University of New South Wales
UNSW Sydney scientist Professor Merlin Crossley. Credit: UNSW

In a landmark study that could lead to new therapies for sickle cell anaemia and other blood disorders, UNSW Sydney-led researchers have used CRISPR gene editing to introduce beneficial natural mutations into blood cells to boost their production of foetal haemoglobin.

The research solves a 50-year-old mystery about how these mutations - which are naturally carried by a small percentage of people - operate and alter the expression of .

The study, by an international team led by UNSW scientist Professor Merlin Crossley, is published in the journal Nature Genetics.

"Our new approach can be seen as a forerunner to 'organic gene therapy' for a range of common inherited blood disorders including beta thalassaemia and sickle cell anaemia," says Professor Crossley, who is also UNSW Deputy Vice-Chancellor Academic.

"It is organic because no new DNA is introduced into the cells; rather we engineer in naturally occurring, benign mutations that are known to be beneficial to people with these conditions.

"It should prove to be a safe and effective therapy, although more research would be needed to scale the processes up into effective treatments."

People with thalassaemia or have defective adult haemoglobin - the vital molecule that picks up oxygen in the lungs and transports it around the body - and require life-long treatment with blood transfusions and medications.

However, some people with these diseases have reduced symptoms because they also carry mutations which switch on the gene that produces foetal haemoglobin, which compensates for their damaged adult haemoglobin.

"The foetal haemoglobin gene is naturally silenced after birth. For 50 years, researchers have been competing furiously to find out how it is switched off, so it can be turned back on," says Professor Crossley.

"Our study, which is the culmination of many years of work, solves that mystery.

"We have found that two genes, called BCL11A and ZBTB7A, switch off the foetal haemoglobin gene by binding directly to it. And the beneficial mutations work by disrupting the two sites where these two genes bind."

"This landmark finding not only contributes to our appreciation of how these globin genes are regulated. It means we can now shift our focus to developing therapies for these genetic diseases using CRISPR to target precise changes in the genome," says Professor Crossley.

The latest findings were spearheaded by three of Crossley's PhD students, over a period of five years. Study co-first author and UNSW PhD student Gabriella Martyn discovered that BCL11A, which was already known to switch off the foetal haemoglobin gene, binds directly to it.

Study co-first author, Dr Beeke Wienert, now working in the department of one of the creators of CRISPR, Professor Jennifer Doudna of the University of California, Berkeley, identified the second repressor gene, ZBTB7A.

Lu Yang, a UNSW PhD student supported by a China Council Scholarship, devised a new method that allowed the visualisation of proteins binding to the foetal haemoglobin gene for the first time.

Dr Alister Funnell, a former post-doctoral researcher at UNSW, who initiated the project, is now a successful team leader working on gene editing at the Altius Institute for Biomedical Sciences in Seattle.

Other members of the group included experts on bioinformatics, Manan Shah and Dr Jon Burdach, and Japanese researchers Ryo Kurita and Dr Yukio Nakamura. UNSW Scientia Fellow Dr Kate Quinlan helped lead the project. The studies relied on the cutting-edge expertise of the Ramaciotti Centre for Genomics at UNSW.

The Australian team's results were first presented at an international conference at Asilomar, California, 18 months ago and a race between UNSW and other labs in the world ensued with the UNSW-led study being published in Nature Genetics.

Sickle cell anaemia and beta thalassemia are the most common single-gene genetic disorders in the world, affecting millions of people, with enormous costs to health systems. These debilitating inherited diseases are highly prevalent in regions where malaria was present, now or in the past, including South East Asia, southern China and India, South America, Africa, the Mediterranean and the Middle East. They are also found in other countries, such as Australia and the United States, due to migrations of populations over time.

The globin genes are perhaps the best understood of any human , with world famous scientists and some of the most competitive labs around the globe having worked on these conditions.

Nobel Laureate Linus Pauling was the first to determine that was due to a change in an amino acid in a protein. Dual Nobel Laureate Fred Sanger was involved in identifying the genetic mutation causing the condition - the first human mutation to be understood at a molecular level.

The structure of the haemoglobin protein was determined by another Nobel Laureate, Max Perutz. And Francis Collins, who led the Human Genome Project, first described some of the mutations analysed in the current work, more than four decades ago.

Explore further: Genome therapy could lead to new treatment for life-threatening blood disorders

More information: Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding, Nature Genetics (2018). nature.com/articles/doi:10.1038/s41588-018-0085-0

Related Stories

Genome therapy could lead to new treatment for life-threatening blood disorders

July 17, 2017
Genome therapy with beneficial natural mutation could lead to new treatment for life-threatening blood disorders

New age of genome editing could lead to cure for sickle cell anemia

May 14, 2015
UNSW Australia researchers have shown that changing just a single letter of the DNA of human red blood cells in the laboratory increases their production of oxygen-carrying haemoglobin - a world-first advance that could lead ...

One day, science may cure sickle cell anaemia

July 9, 2014
Genetic mutations that affect our blood cells' haemoglobin are the most common of all mutations. It has been estimated that around 5% of the world's population carry a defective globin gene.

The slow climb from innovation to cure—treating anaemia with gene editing

October 19, 2016
The ability to precisely edit DNA via CRISPR technology has emerged as the one of the most powerful advances in biology. A new paper showing repair of a genetic mutation in human blood cells represents an important step towards ...

Study tracks worldwide spread of beneficial blood cell gene variant

July 29, 2014
Two beneficial variants of a gene controlling red blood cell development have spread from Africa into nearly all human populations across the globe, according to a new study led by King's College London. The international ...

East and West African sickle cell anaemia are genetically similar

November 6, 2014
Sickle cell anaemia is most common in Africa and up to 11,000 children are born with the condition every year in Tanzania alone. Yet most of what is known about the genetic basis of this inherited disease comes from studies ...

Recommended for you

Critical role of DHA on foetal brain development revealed

August 17, 2018
Duke-NUS researchers have found evidence that a natural form of Docosahexaenoic Acid (DHA) made by the liver called Lyso-Phosphatidyl-Choline (LPC-DHA), is critical for normal foetal and infant brain development, and that ...

New algorithm could improve diagnosis of rare diseases

August 17, 2018
Today, diagnosing rare genetic diseases requires a slow process of educated guesswork. Gill Bejerano, Ph.D., associate professor of developmental biology and of computer science at Stanford, is working to speed it up.

Gene silencing critical for normal breast development

August 17, 2018
Researchers have discovered that normal breast development relies on a genetic 'brake', a protein complex that keeps swathes of genes silenced.

Officials remove special rules for gene therapy experiments

August 16, 2018
U.S. health officials are eliminating special regulations for gene therapy experiments, saying that what was once exotic science is quickly becoming an established form of medical care with no extraordinary risks.

Genetic link discovered between circadian rhythms and mood disorders

August 15, 2018
Circadian rhythms are regular 24-hour variations in behaviour and activity that control many aspects of our lives, from hormone levels to sleeping and eating habits.

Ovarian cancer genetics unravelled

August 14, 2018
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.